90% have completed 12-month follow-up in Stayble Therapeutics' ongoing Phase IIb study
Stayble Therapeutics AB ("Stayble" or the "Company") announces that approximately 90% of all patients in the Company's ongoing Phase IIb study in degenerative disc disease have completed their 12-month follow-up. The study remains of high quality with a low drop-out rate.With all patients having completed their six-month visit in February 2023, Stayble was able to secure all critical data to evaluate the primary endpoint of the Phase IIb study. Due to the continued low number of dropouts from the study, Stayble has now successfully completed the 12-month follow-up in approximately 90% of